Maravai Lifesciences Holdings (MRVI) Liabilities and Shareholders Equity (2020 - 2026)

Maravai Lifesciences Holdings' Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $713.2 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 25.69% year-over-year to $713.2 million in Q1 2026; TTM through Mar 2026 was $3.2 billion, a 31.13% decrease from a year earlier, with the FY2025 full-year figure at $770.6 million, down 23.57% from the prior year.
• Liabilities and Shareholders Equity declined to $713.2 million in Q1 2026 per MRVI's latest filing, from $770.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $2.3 billion in Q1 2023 and bottomed at $713.2 million in Q1 2026.
• The 5-year median for Liabilities and Shareholders Equity is $1.4 billion (2024), against an average of $1.6 billion.
• Across the five-year window, Liabilities and Shareholders Equity jumped 51.15% in 2022 and sank 43.63% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $2.3 billion in 2022, then slumped by 34.83% to $1.5 billion in 2023, then plunged by 32.22% to $1.0 billion in 2024, then retreated by 23.57% to $770.6 million in 2025, then fell by 7.44% to $713.2 million in 2026.
• Per Business Quant, the three latest MRVI Liabilities and Shareholders Equity figures stand at $713.2 million (Q1 2026), $770.6 million (Q4 2025), and $849.2 million (Q3 2025).